Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Emergent BioSolutions Inc. Director's Dealing 2018

Sep 18, 2018

32870_dirs_2018-09-18_f2134ba4-11c1-419e-bfb2-dbb22d4fc257.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2018-09-14

Reporting Person: Abdun-Nabi Daniel (Director, CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-09-14 Common Stock M 28220 $13.38 Acquired 194787 Direct
2018-09-14 Common Stock S 28220 $65.00 Disposed 166567 Direct
2018-09-17 Common Stock M 1319 $13.38 Acquired 167886 Direct
2018-09-17 Common Stock S 1319 $65.00 Disposed 166567 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2018-09-14 Stock Option (Right to Buy) $13.38 M 28220 Acquired 2020-03-11 Common Stock (28220) Direct
2018-09-17 Stock Option (Right to Buy) $13.38 M 1319 Acquired 2020-03-11 Common Stock (1319) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1936 Indirect

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.

F2: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

F3: Consists of an option granted under the company's stock incentive plan as amended and restated.

F4: The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant.